Scribe Therapeutics的动态

???? ?????????????? ??&?? ?????????????????? ???? 2024!????? ?? Did you know the number of biopharma M&A deals has more than doubled in Q1 of 2024 compared to last year? From 6 to 13, totaling 47 in the last twelve months! ?? ????????? ?????????? ???? ?????? ????????????: ? AstraZeneca shakes up oncology with deals for Fusion Pharmaceuticals & Gracell Biotechnologies! ?? ? Merck Life Science acquires T-cell magic from Harpoon Therapeutics! ?? ?? ???????? ????????’?? ????????????????????: ? Takeda could spend up to $1.2 billion on a new cancer fighter with Kumquat Biosciences Inc.! ??? ? Boehringer Ingelheim and Ochre Bio tackle liver disease with a billion-dollar RNA therapy bet! ?? ? Ipsen is investing $1.8 billion in neuroscience R&D with Skyhawk Therapeutics! ?? ?? With Big Pharma's unwavering interest, 2024 is set to be a groundbreaking year for biotech M&A. What’s your take? Could this be the boost we've been waiting for in innovation and competition? ?? #Biotech #MergersAndAcquisitions #Innovation #PharmaIndustry #FutureOfPharma

?? Live from the 19th BioPharma Drug Discovery Nexus Conference! Join Lars Nieba CEO at Engimmune Therapeutics, as he unveils groundbreaking insights on coupling protein engineering with AI to develop multi-specific, soluble TCR-based cell engagers for oncology and auto-immune diseases. Don't miss this enlightening session! #BioPharma #DrugDiscovery #Innovation #NexusConference #Switzerland #Proteinengineering #AI #Cell #TCR #ImmuneDiseases #ProcurementDirect #LiveUpdate #ConferenceLive #DiscoveryConference #EuropeEvent

After inking an up to $6 billion partnership with Poseida Therapeutics in 2022, Roche is now paying $1 billion upfront to acquire all of its off-the-shelf cell therapy and genomic medicines partner. The Swiss pharma giant is gaining a pipeline of oncology, autoimmune and neurology treatment candidates. “We do really think this is only the beginning. And when you think about it this way, then the answer becomes almost a foregone conclusion that there is so much complementarity, there is so much potential, we should become one,” Aviv Regev, head of research and early development at Genentech, said in an interview with Endpoints News. #roche #poseida #sandiegobiotech #biotech #pharma #biotechacquisition #allogeneic #offtheshelf #celltherapy #genomicmedicines #multiplemyeloma #hemophiliaa #hereditaryangioedema

Join us tomorrow at the 2nd Oligonucleotide Manufacturing Symposium, featuring Technical Director Adrian La Porta. The event will take place at the CPI Medicines Manufacturing Innovation Centre in Glasgow, where key stakeholders from the pharmaceutical sector will gather to discuss emerging process technologies in oligonucleotide therapeutics. These innovative DNA or RNA fragments are transforming the treatment of diseases by modulating protein expression through various mechanisms. The symposium will focus on developing and scaling these processes to manufacture therapies effectively. These advances have the potential to address a broad range of diseases, from cancer to Alzheimer’s, paving the way for new treatments for conditions currently deemed untreatable and improving therapies for widespread illnesses like heart disease. Learn more: https://lnkd.in/eWHKy2kC #BrydenWood #OligonucleotideSymposium #PharmaceuticalInnovation #pharma

Eder Therapeutics and xcube.bio have announced a strategic cooperation to facilitate the market entry and commercialization of biotech assets in Canada and Europe. The two companies will coordinate their offerings to biopharma innovators in their respective regions and leverage the numerous synergies that exist between the healthcare systems of Europe and Canada. The collaboration will specifically focus on product profiling, regulatory processes, Health Technology Assessment (HTA), and medical communication, and commercialization - ultimately benefiting patients and biopharma partners. ? "Eder Therapeutics is thrilled to combine its unique depth in the Canadian market with the breadth of a European platform like xcube.bio. This partnership will enhance access to innovative treatments for Canadian patients, which is our ultimate goal," said Jared Rhines, CEO of Eder Therapeutics. ? Pierre-Henri Belin, CEO of xcube.bio, stated, "xcube.bio, a European market-entry specialist, has found a valued like-minded partner in Eder Therapeutics. We look forward to expanding this cooperation to accelerate patient access and provide added value to our biopharma partners." ? An initial phase of expert cooperation will begin with Eder Therapeutics' investigational gene therapy for Lipoprotein Lipase Deficiency. #biopharma #partnering #commercialization

?? Amanda Roche of Unity Bank is recognized as a new leader in banking by NJ Bankers Association. #Leadership #Banking ?? Poseida Therapeutics will be acquired by Roche Holdings for up to $1.5 billion, enhancing Roche's pharmaceuticals division with Poseida's non-viral, TSCM-rich CAR-T therapies and genetic medicines. #Biotech #MergersAndAcquisitions ?? Roche announces definitive agreement to acquire Poseida Therapeutics, bringing in Poseida's pioneering donor-derived CAR-T cell therapies, R&D portfolio, and manufacturing capabilities. #HealthTech #Innovation ?? Roche and Genentech report updates on Phase III SKYSCRAPER-01 study, evaluating tiragolumab with Tecentriq? for patients with high PD-L1, locally advanced/metastatic non-small cell lung cancer. #CancerResearch #DataPorium #Roche #PoseidaTherapeutics #UnityBank #Genentech At DataPorium, we track the financial performance, product sales, market share, and social network analysis. We also track the trends of nearly 1,000 products every quarter. ?? Want to see more? Head over to https://lnkd.in/duDAwekv and explore! ?? Visit our LinkedIn page https://lnkd.in/gJ2iKqKw today for exclusive updates—completely free!

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Roche buys out CAR-T partner Poseida for $1B upfront: Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning. The Basel-based pharma giant will pay $9 per share in upfront cash, giving Poseida ... #lucidquest #genetherapy #celltherapy

Hope everyone had a great week! I wanted to share some of this weeks Life Science Industry Highlights: Apollomics updated their strategic focus and announced key leadership changes, aiming to streamline operations and prioritize their lung cancer trials. Cerus welcomed Dean Gregory Gregory to their Board of Directors, bringing in new expertise to drive forward their mission. Mendel.ai unveiled a groundbreaking neuro-symbolic AI system, outperforming GPT-4 in a new study for automatic cohort retrieval. Semnur Pharmaceuticals, Inc., a subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) signed a letter of intent for a proposed business combination. Adicet Bio, Inc Bio received FDA Fast Track Designation for ADI-270 in metastatic/advanced clear cell renal cell carcinoma, accelerating the development of this promising treatment. AusperBio highlighted major advances in the clinical development of AHB-137. Biostar Pharmaceuticals Inc Pharma got FDA clearance for an IND application for a Phase 2 study of Utidelone Injection (UTD1) in HER2- breast cancer brain metastasis. CellProthera SAS and BioCardia, Inc. successfully collaborated on a Phase II trial of ProtheraCytes for treating acute myocardial infarction. #Biotech #Pharma #LifeScience #HealthcareInnovation #AIinHealthcare #ClinicalTrials #FDAApproval #Biopharma #LifeSciences #MedicalResearch #DrugDevelopment #HealthTech #Biotechnology #Pharmaceuticals #BiotechNews #Innovation #Healthcare #MedTech #ResearchAndDevelopment

Gene&Cell Therapy >> Roche buys out CAR-T partner Poseida for $1B upfront: Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning. The Basel-based pharma giant will pay $9 per share in upfront cash, giving Poseida ... #lucidquest #genetherapy #celltherapy

?????????????? ?????????????????????? ?????????????????? ???????????????? ???????? ???????? ?????????? ??/?? ??????????????????? ?????????? ?????? ???????? ?????????????????? Avidity Biosciences, Inc. (Nasdaq: RNA) Avidity Biosciences, Inc., a biopharmaceutical company pioneering RNA therapeutics, shared positive initial data from the Phase 1/2 FORTITUDE? trial of AOC 1020 (delpacibart braxlosiran, del-brax). The data show unprecedented and consistent reductions of over 50% in DUX4 regulated genes, functional improvement trends, and favorable safety in people with facioscapulohumeral muscular dystrophy (FSHD). This has led Avidity to expedite the initiation of registrational cohorts in the FORTITUDE? study. FSHD, a rare hereditary disorder, causes progressive muscle function loss, significant pain, fatigue, and disability. Del-brax is the first investigational therapy targeting DUX4, the abnormal gene expression causing FSHD. Currently, no approved therapies exist for FSHD treatment. Key findings from the FORTITUDE trial include: Over 50% mean reductions in DUX4 regulated genes. Mean reductions of 25% or more in circulating biomarkers and creatine kinase. Trends of functional improvements in muscle strength and function. Favorable safety with mild or moderate adverse events and no serious adverse events. Dr. Jeffrey M. Statland from the University of Kansas Medical Center highlighted the potential of del-brax to change the course of FSHD by improving muscle strength and function. The data will be presented at the 31st Annual FSHD Society International Research Congress in June 2024. Sarah Boyce Sarah Boyce, CEO of Avidity, emphasized the urgency of developing del-brax as a first-in-class therapy for FSHD, showcasing the potential of their AOC platform to revolutionize RNA therapeutics. Mark Stone, CEO of FSHD Society, expressed hope that del-brax could offer significant relief for those affected by FSHD. #Biotech #RNAtherapeutics #FSHD #ClinicalTrials #AvidityBiosciences #MedicalResearch #HealthcareInnovation #RareDisease #DrugDevelopment #Pharmaceuticals #RNA #AntibodyOligonucleotideConjugates